Tafasitamab
Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[1]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD19 |
| Clinical data | |
| Trade names | Monjuvi |
| Other names | tafasitamab-cxix, MOR208, Xmab5574 |
| AHFS/Drugs.com | Monjuvi |
| License data |
|
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6550H10092N1724O2048S52 |
| Molar mass | 147425.93 g·mol−1 |
Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody.[1][2]
Tafasitamab was approved for medical use in the United States in July 2020.[3][2]
Medical uses
Tafasitamab, in combination with lenalidomide, is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[1]
Society and culture
Names
Tafasitamab is the international nonproprietary name (INN).[4]
gollark: Actually, this is the politics discussion channel.
gollark: US healthcare is an incredibly eldritch hybrid of giant monopolistic companies and accursedly complex regulation.
gollark: Something something baumol cost disease.
gollark: .
gollark: The hardest one I ever did was the British Informatics Olympiad, which was intensely ae ae ae ae
References
- "Monjuvi (tafasitamab-cxix) for injection, for intravenous use" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 31 July 2020.
- "FDA Approves Monjuvi (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)" (Press release). MorphoSys AG. 31 July 2020. Retrieved 31 July 2020 – via Business Wire.
- "Monjuvi: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 31 July 2020.
- World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1): 118–9. hdl:10665/330896. License: CC BY-NC-SA 3.0 IGO.
External links
- "Tafasitamab". Drug Information Portal. U.S. National Library of Medicine.
- "MOR208 (tafasitamab)". MorphoSys AG.
- Clinical trial number NCT02399085 for "A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL (L-MIND)" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.